Clinical trial NCT03283826: Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Official title: A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Primary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Keywords: Multiple Sclerosis (MS)
Primary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Epstein-Barr Virus (EBV)
EBV-associated Multiple Sclerosis
Inflammation
Central Nervous System
Autoimmune Disease
Autoimmunity
Demyelination
Cell Therapy
T-cell
Allogeneic
EBV viremia
Off-the-shelf (T cells)
Lead sponsor: Atara Biotherapeutics
Sponsor class: INDUSTRY
First posted: 2017-09-14
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis \[PPMS\] and secondary progressive multiple sclerosis \[SPMS\]).

Detailed description: This is a multicenter, 2 part study in adult participants with progressive forms of MS (PPMS/SPMS) with an open-label, single-arm, sequential dose-escalation period (Part 1) and a double-blind, randomized, placebo-controlled dose-expansion period (Part 2) followed by open-label extension (OLE) period. Part 2 and the OLE have been initiated by the sponsor's discretion based on a review of data from the dose-escalation cohorts.

This study will evaluate the safety and efficacy of ATA188 administered by intravenous (IV) infusion. ATA188 will be selected for each participant based on matching 2 or more human leukocyte antigen (HLA) alleles shared between ATA188 and the participant, at least 1 of which is a HLA-restricting allele.

In Part 1, participants received 2 cycles of ATA188 and entered 12 months follow-up period after the last dose of ATA188. Participants who completed at least the first year of the dose-escalation period and were active in the study have entered the OLE period. In OLE period, participants will receive the same RP2D assigned to Part 2 participants at the time of the Part 1 participant's first dose in each year of the OLE. In OLE period, participants will receive 1 cycle of ATA188 treatment every 12 months (Q12M) for up to 4 years (ie, Years 2 to 5). Otherwise, end of study (EOS) visit will be conducted at 24 months after Cycle 1 Day 1.

In Part 2, participants will be randomized in 1:1 ratio to receive ATA188 at the RP2D or matching placebo, stratified by progressive MS diagnosis (PPMS vs SPMS) and any prior exposure to anti-CD20 therapy (yes vs no). Participants will receive 2 cycles of ATA188 at the RP2D or matching placebo and will be followed for at least 12 months after the first dose of study drug (ie, Year 1). In second year (Year 2), participants who received placebo in Year 1 will receive 2 cycles of ATA188 at the RP2D assigned at randomization and participants who received ATA188 at the RP2D in Year 1 will receive 1 cycle of ATA188 (at the RP2D assigned at randomization) and 1 cycle of placebo to maintain the blind. Participants who complete Year 2 will enter the OLE period to receive ATA188 Q12M for up to 3 years (ie, Years 3 to 5) at the RP2D that was last selected by the sponsor for Part 2. The end of study visit will be scheduled at 5 years (60 months) after the first dose of study drug (ie, Cycle 1 Day 1).

Based on interim analysis, the recruitment for Parts 1and 2 have completed.

Eligibility criteria: Inclusion Criteria:

* For Part 1: History of progressive forms of MS (PPMS or SPMS), as defined by the 2010 Revised McDonald criteria for the diagnosis of MS
* For Part 1: 18 to \< 66 years of age
* For Part 1: EDSS scores of 3.0 to 7.0. Participants with EDSS scores of 6.5 to 7.0 must retain measurable upper limb function as assessed by the 9-hole Peg Test (9HPT).
* For Part 2: Current diagnosis of a progressive form of MS (PPMS or SPMS) as defined by the 2017 Revised McDonald criteria
* For Part 2:18 to \< 61 years of age
* For Part 2:EDSS scores of 3.0 to 6.5
* Positive EBV serology
* Willing and able to provide written informed consent

Exclusion Criteria:

* Clinical relapse as follows: For Part 1: Active clinical relapse between providing informed consent and the first dose of study drug. For Part 2: Documented clinical and/or radiological relapse for 2 years prior to screening, including gadolinium (Gd)-enhancing lesion(s) on any brain MRI scans available during this period (A participant will also be considered ineligible if any clinical and/or radiological relapse is reported between screening and the first dose of study drug.)
* Concurrent serious uncontrolled or unresolved medical condition, such as infection, limiting protocol compliance or exposing the subject to unacceptable risk
* Positive serology and/or nucleic acid testing (NAT) for human immunodeficiency virus (HIV), active hepatitis B virus (HBV) infection or carrier status for HBV, active hepatitis C virus (HCV) infection
* For Part 1: Positive serology for syphilis or human T cell lymphotrophic virus I/II
* Uncontrolled psychosis, uncontrolled depression or suicide risk, substance dependence, or any other psychiatric condition that may compromise the ability to participate in this trial
* Clinically significant abnormalities of full blood count, renal function, or hepatic function
* Any contraindication to MRI and/or Gd, eg., any object that is reactive to strong static magnetic, pulsed-gradient fields including any metallic fragments or foreign body (eg, aneurysm clip\[s\], pacemakers, electronic implants, shunts)
* Any history of cancer (as exceptions, successfully treated non-melanoma skin cancer or carcinoma in situ of the cervix with a \< 5% chance of recurrence within 12 months of providing informed consent are allowed.)
* Prior therapy with corticosteroids (within 2 weeks before Cycle 1 Day 1)
* Prior therapy (30 days) B-cell depleting agent (eg, anti-CD20 agents such as ocrelizumab); participant must be progressing despite therapy to be eligible
* For Part 1: Prior therapy (6 half-lives or 30 days whichever is longer) with cladribine, glatiramer acetate, interferon β, dimethyl fumarate, methotrexate, azathioprine, cyclosporine, fingolimod, natalizumab, teriflunomide, mitoxantrone, cyclophosphamide, any other immunosuppressant or cytotoxic therapy (other than steroids), antithymocyte globulin or similar anti-T-cell antibody therapy, or any other investigational product
* For Part 1: Any previous treatment with alemtuzumab, ablative stem cell transplant, or EBV T-cell therapy
* For Part 2: Prior therapy (6 half-lives or 30 days whichever is longer) with IV immunoglobin, plasmapheresis, Bruton's tyrosine kinase inhibitors, all sphingosine 1-phosphate receptor modulators (eg, fingolimod), glatiramer acetate, interferon β, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators (eg, dimethyl fumarate), methotrexate, azathioprine, cyclosporine, natalizumab, teriflunomide, mitoxantrone, cyclophosphamide, any other immunosuppressant or cytotoxic therapy (other than steroids), antithymocyte globulin or similar anti-T-cell antibody therapy, or any other investigational product
* For Part 2: Any previous treatment with cladribine, alemtuzumab, ablative stem cell transplant, or EBV T-cell therapy
* Unresolved reactions from previous therapies that may, in the investigator's opinion, impact the safety of the participant or the conduct of this study
* Unwilling to use protocol specified contraceptive methods
* Women who are breastfeeding
* Pregnancy
* Inability or unwillingness to comply with study procedures

Primary outcomes:
measure: Part 1: Incidence of adverse events
timeFrame: At 12 months after the first dose of study drug
measure: Part 1: Incidence of clinically significant changes in laboratory tests, electrocardiograms (ECGs), and vital signs
timeFrame: At 12 months after the first dose of study drug
measure: Part 1: Recommended Part 2 dose of ATA188 monotherapy
timeFrame: Day 1 to Day 35 of Cycle 1 for each participant in dose escalation part (approximately 1 year)
measure: Part 2: Percentage of participants with confirmed expanded disability status scale (EDSS) improvement at 12 months
timeFrame: At 12 months after the first dose of study drug
Secondary outcomes:
measure: Part 1: Change from baseline in EDSS score
timeFrame: At 12 months after the first dose of study drug
measure: Part 2: Percentage of participants with confirmed EDSS improvement at 15 months
timeFrame: At 15 months after the first dose of study drug
measure: Part 2: Percentage of participants with sustained disability improvement (SDI; ie, confirmed EDSS improvement or 20% decrease in timed 25-foot walk [T25W]) at 12 months
timeFrame: At 12 months after the first dose of study drug
measure: Part 2: Percentage of participants with SDI at 15 months
timeFrame: At 15 months after the first dose of study drug
measure: Part 2: Change from baseline in immunoglobulin G (IgG) index
timeFrame: At 9 months after the first dose of study drug
Other outcomes:
measure: Change from baseline in cervical spinal cord volume on MRI scans
timeFrame: At 12 months after the first dose of study drug
measure: Change from baseline in whole brain volume on MRI scans
timeFrame: At 12 months after the first dose of study drug
measure: Change from baseline in number of Gd-enhancing and new or enlarging T2 lesions on brain MRI scans
timeFrame: At 12 months after the first dose of study drug
measure: Change from baseline in IgG production
timeFrame: At 12 months after the first dose of study drug
Locations:
city: La Jolla
country: United States
facility: University of California, San Diego
state: California
city: Los Angeles
country: United States
facility: Kaiser Permanente MS Clinic Los Angeles
state: California
city: Palo Alto
country: United States
facility: Stanford University
state: California
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
city: Fort Collins
country: United States
facility: Advanced Neurology
state: Colorado
city: Maitland
country: United States
facility: Neurology Associates, PA-Maitland
state: Florida
city: Tampa
country: United States
facility: University of South Florida, Morsani College of Medicine
state: Florida
city: Fort Wayne
country: United States
facility: Fort Wayne Neurological Center
state: Indiana
city: Kansas City
country: United States
facility: University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center
state: Kansas
city: New Orleans
country: United States
facility: Ochsner Clinic Foundation
state: Louisiana
city: Wellesley
country: United States
facility: Dragonfly Research
state: Massachusetts
city: Saint Louis
country: United States
facility: Washington University in St. Louis
state: Missouri
city: Amherst
country: United States
facility: Dent Neurologic Institute
state: New York
city: New York
country: United States
facility: Columbia University Medical Center-The Neurological Institute of New York
state: New York
city: Rochester
country: United States
facility: University of Rochester Medical Center - URMC
state: New York
city: Mooresville
country: United States
facility: PMG Research of Piedmont Healthcare
state: North Carolina
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Greer
country: United States
facility: Premier Neurology P.C.
state: South Carolina
city: Franklin
country: United States
facility: Advanced Neurosciences Institute ANI - Franklin
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt Comprehensive Multiple Sclerosis Center
state: Tennessee
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
city: Vienna
country: United States
facility: MS Center of Greater Washington
state: Virginia
city: Spokane
country: United States
facility: Inland Northwest Research LLC
state: Washington
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
city: Liverpool
country: Australia
facility: Liverpool Hospital
state: New South Wales
city: Brisbane
country: Australia
facility: Royal Brisbane and Women's Hospital
state: Queensland
city: Southport
country: Australia
facility: Griffith University, School of Medicine
state: Queensland
city: Burnaby
country: Canada
facility: Fraser Health Multiple Sclerosis Clinic
state: British Columbia
city: Toronto
country: Canada
facility: Unity Health Toronto/St. Michael's Hospital
state: Ontario
city: Greenfield Park
country: Canada
facility: Recherche Sepmus Inc.
state: Quebec
Study officials:
affiliation: Atara Biotherapeutics
name: Kiren Kresa-Reahl, MD
role: STUDY_DIRECTOR
References:
citation: Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler. 2014 Oct;20(11):1541-4. doi: 10.1177/1352458514521888. Epub 2014 Feb 3.
citation: Pender MP, Csurhes PA, Burrows JM, Burrows SR. Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clin Transl Immunology. 2017 Jan 20;6(1):e126. doi: 10.1038/cti.2016.87. eCollection 2017 Jan.